Observational Usage Study of Statins in Primary Care in France
NCT ID: NCT00680082
Last Updated: 2010-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2100 participants
OBSERVATIONAL
2008-02-29
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francois Morand
Role: PRINCIPAL_INVESTIGATOR
Cegedim Strategic Data - Boulogne Billancourt - France
Jean Dallongeville
Role: STUDY_CHAIR
Institut Pasteur - Inserm U744 - Lille -France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Hefei, Anhui, China
Research Site
Chongqing, Chongqing Municipality, China
Research Site
Fuzhou, Fujian, China
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
Research Site
Xiamen, Guangdong, China
Research Site
Zhongshan, Guangdong, China
Research Site
Zhengzhou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Changsha, Hunan, China
Research Site
Nanjing, Jiangsu, China
Research Site
Suzhou, Jiangsu, China
Research Site
Wuxi, Jiangsu, China
Research Site
Nanchang, Jiangxi, China
Research Site
Jinan, Shandong, China
Research Site
Qingdao, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Taiyuan, Shanxi, China
Research Site
Xi’an, Shanxi, China
Research Site
Chengdu, Sichuan, China
Research Site
Kunming, Yunnan, China
Research Site
Hangzhou, Zhejiang, China
Research Site
Ningbo, Zhejiang, China
Research Site
Rui’an, Zhejiang, China
Research Site
Wenzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CFR-CRE-2007/2
Identifier Type: -
Identifier Source: org_study_id